First AD

Second AD

Clinical Scenario: Treatment Selection in the third line and beyond in cGVHD

Video content above is prompted by the following:

Dr Holtan: Please read this clinical scenario:

 Four months after having undergone allogenic hematopoietic stem transplant, a patient presents to the clinic with rashes over a large portion of his body and dry eyes. Based on clinical presentation and lab results, a diagnosis of moderate cGVHD is established. Patient was treated with steroids and subsequent calcineurin inhibitors for 4 to 6 weeks but showed little improvement in cGVHD symptoms.

What other treatments could be used in such patients once steroid refractoriness is established?

Are there factors you consider when choosing an alternate treatment option (efficacy, safety profile, clinical manifestations)?

Video Series

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

My Treatment Approach: Optimizing Treatment for Chronic GVHD

Medical experts discuss treatment selection for a specific clinical scenario. 